Pneumococcal Adult-dose Ranging Immunization Study

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

February 28, 2005

Study Completion Date

February 28, 2005

Conditions
Pneumonia
Interventions
BIOLOGICAL

PCV7, Prevnar®

Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.

BIOLOGICAL

Pneumovax 23

Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.

Trial Locations (2)

98101

Group Health Research Institute, Seattle

98108

VA Puget Sound Health Care System, Seattle

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

lead

Kaiser Permanente

OTHER

NCT00169234 - Pneumococcal Adult-dose Ranging Immunization Study | Biotech Hunter | Biotech Hunter